Obsessive-compulsive disorder: Unearthing a hidden problem

Cleveland Clinic Journal of Medicine

Volumn 70, Issue 10, 2003, Pages 824-840

  El Sayegh, Samar ^a   Bea, Scott ^a   Agelopoulos, Angela ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BUSPIRONE; CITALOPRAM; CLOMIPRAMINE; CLONAZEPAM; FLUOXETINE; FLUVOXAMINE MALEATE; HALOPERIDOL; NEUROLEPTIC AGENT; PAROXETINE; PLACEBO; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TRICYCLIC ANTIDEPRESSANT AGENT;

AGGRESSIVENESS; BEHAVIOR THERAPY; BODY WEIGHT DISORDER; CLINICAL FEATURE; COGNITIVE THERAPY; COMPULSION; CONSTIPATION; DRUG HALF LIFE; FAMILY COUNSELING; FATIGUE; HEADACHE; HUMAN; INSOMNIA; MEDICAL DECISION MAKING; MENTAL DISEASE; NAUSEA; NEUROSURGERY; OBSESSION; OBSESSIVE COMPULSIVE DISORDER; ORTHOSTATIC HYPOTENSION; PATIENT ATTITUDE; PATIENT CARE; PATIENT REFERRAL; PHYSICIAN; PRIMARY MEDICAL CARE; PSYCHOLOGIC ASSESSMENT; PSYCHOTHERAPY; QUALITY OF LIFE; RELIGION; REVIEW; SEIZURE; SEXUAL BEHAVIOR; SEXUAL DYSFUNCTION; SHAME; SOMNOLENCE; SYMPTOM; TREATMENT OUTCOME; URINE RETENTION; VERTIGO; VISUAL IMPAIRMENT; WEIGHT GAIN; XEROSTOMIA;

EID: 0142217849     PISSN: 08911150     EISSN: None     Source Type: Journal    
DOI: 10.3949/ccjm.70.10.824     Document Type: Review

References (26)

1. Hollander E, Kwon JH, Stein DJ, et al. Obsessive-compulsive and spectrum disorders: overview and quality of life issues. J Clin Psychiatry 1996; 57(suppl 8):3-6.
2. Karno M, Golding JM, Sorenson SB, Burnam MA. The epidemiology of obsessive-compulsive disorder in five US communities. Arch Gen Psychiatry 1988; 45:1094-1099.
3. Rasmussen SA, Eisen JL. The epidemiology and differential diagnosis of obsessive-compulsive disorder. J Clin Psychiatry 1992; 53(suppl):4-10.
4. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington, DC: American Psychiatric Association, 1994.
5. Weissman MM, Bland RC, Canino GJ, et al. The cross national epidemiology of obsessive-compulsive disorder. The Cross National Collaborative Group. J Clin Psychiatry 1994; 55:3(suppl):5-10.
6. Sasson Y, Zohar J, Chopra M, et al. Epidemiology of obsessive-compulsive disorder: a world view. J Clin Psychiatry 1997; 58(suppl 12):7-10.
7. Attiullah N, Eisen JL, Rasmussen SA. Clinical features of obsessive-compulsive disorder. Psychiatr Clin North Am 2000; 23:469-491.
8. March JS, Frances A, Kahn DA, Carpenter D, editors. The expert consensus guideline series: treatment of obsessive-compulsive disorder. J Clin Psychiatry 1997; 58(suppl 4).
9. Foa EB, Franklin ME. Psychotherapies for obsessive-compulsive disorder: a review. In: Obsessive-Compulsive Disorder. New York: John Wiley & Sons Ltd, 2000;93-146.
10. Foa EB, Kozak MJ. Psychological treatment for obsessive-compulsive disorder. In: Mavissakalian MR, Prien RF, editors. Long-Term Treatments of Anxiety Disorders. Washington, DC: American Psychiatric Press, 1996;285-309.
11. Schwartz JM, Stoessel PW, Baxter LR, et al. Systemic changes in cerebral glucose metabolic rate after successful behavior modification treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 1996; 53:109-113.
12. Hyman BM, Pedrick C. Where to get help? In The OCD Workbook. Oakland, Ca: New Harbinger, 1999:199-204.
13. Hollander E, Kaplan A, Allen A, Cartwright C. Pharmacotherapy for obsessive-compulsive disorder. Psychiatr Clin North Am 2000; 23:643-656.
14. Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 1991; 48:730-738.
15. Stahl SM. Essential Psychopharmacology: Neuroscientific Basis and Practical Applications. Cambridge University Press, 1996:131-166.
16. Vythilingum B, Cartwright C, Hollander E. Pharmacotherapy of obsessive-compulsive disorder: experience with the selective serotonin reuptake inhibitors. Int Clin Psychopharmacol 2000; 15(suppl 2):S7-S13.
17. Montgomery SA, McIntyre A, Osterheider M, et al. A double-blind placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. Eur Neuropsychopharmacol 1993; 3:143-152.
18. Koran LM, Hackett E, Rubin A, et al. Efficacy of sertraline in the long-term treatment of obsessive-compulsive disorder. Am J Psychiatry 2002; 159:88-95.
19. Jenike MA, Rauch SL. Managing the patient with treatment-resistant obsessive-compulsive disorder: current strategies. J Clin Psychiatry 1994; 55(suppl):11-17.
20. Rasmussen SA, Eisen JL. Treatment strategies for chronic and refractory obsessive-compulsive disorder. J Clin Psychiatry 1997; 58(suppl 13):9-13.
21. Greenberg BD, Murphy DL, Rasmussen SA. Neuroanatomically based approaches to obsessive-compulsive disorder. Psychiatr Clin North Am 2000; 23:671-686.
22. Hollander E. Obsessive-compulsive disorder: the hidden epidemic. J Clin Psychiatry 1997; 58(suppl 12):3-6.
23. Trivedi MH. Functional neuroanatomy of obsessive-compulsive disorder. J Clin Psychiatry 1996; 57(suppl 8):26-36.
24. Micallef J, Blin O. Neurobiology and clinical pharmacology of obsessive-compulsive disorder. Clin Neuropharmacol 2001; 24:191-207.
25. Saxena S, Brody AL, Maidment KM, et al. Localized orbitofrontal and subcortical metabolic changes and predictors of response to paroxetine treatment in obsessive-compulsive disorder. Neuropsychopharmacology 1999; 21:683-693.
26. Kaplan HI, Sadock BJ. Comprehensive Textbook of Psychiatry. 6th ed. Vol 1. Baltimore: Williams & Wilkins, 1995:1218-1227.